The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Challenges and advances in the treatment of HR-MDS: alloSCT and novel agents
Idoroenyi Amanam, MD, City of Hope, Duarte, CA, comments on the challenges and advances in the treatment of high-risk myelodysplastic syndromes (HR-MDS). He highlights that improvements need to be made in conditioning and GvHD prophylaxis for allogeneic stem cell transplantation (alloSCT), and then goes on to discuss targeted and cellular therapies in the pipeline. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
High-risk MDS is a very difficult disease. As a transplantor, currently we only have one curative therapy which is allogeneic stem cell transplant. I think we still have room for improvement there. So we have GvHD prophylaxis regimens that we’re evaluating, conditioning regimens that we’re looking at as well, in addition to maintenance modalities post-transplant in order to improve outcomes...
High-risk MDS is a very difficult disease. As a transplantor, currently we only have one curative therapy which is allogeneic stem cell transplant. I think we still have room for improvement there. So we have GvHD prophylaxis regimens that we’re evaluating, conditioning regimens that we’re looking at as well, in addition to maintenance modalities post-transplant in order to improve outcomes. So I think there’s still room for improvement in this curative treatment that we have. In addition to that, I think all of us have been interested in targeted therapies, cellular therapies. So we have CAR-T, we have CAR-NK, looking at targeting CD123, CD33. You know that data still isn’t mature yet but very interested to see what the outcomes are especially with the CAR-NK.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
BMS: Advisory.
